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Antibody diversity is generated during 
B cell development by the rearrange-
ment of variable (V), diversity (D), and 
joining (J) segments of immunoglobulin 
(Ig) genes. Both alleles of each Ig locus 
can initiate rearrangement, but only one 
allele successfully rearranges. As soon as 
this occurs, the other allele is prevented 
from following suit. This mechanism, 
known as allelic exclusion, 
guarantees that each B 
cell produces antibodies 
specific for just one an-
tigen. In her laboratory 
at New York Univer-
sity (NYU), Jane Skok 
studies how exclusion 
is established.
Skok’s initial foray 
into research involved 
dissecting the genetics of 
the complement cascade with Ellen 
Solomon at Cancer Research UK (1). 
But immediately after earning her Ph.D., 
Skok left science to care for her ill child. 
When she returned nearly a decade later, 
she had to start from scratch. After getting 
up to speed with a Master's in immunol-
ogy, she joined Amanda Fisher’s lab, 
where she gravitated toward B cells and 
the question of allelic exclusion.
Skok has since helped define some 
of the steps that make exclusion possible. 
She discovered that the excluded Ig 
allele gets sent to repressive DNA do-
mains near the centromere, whereas the 
productive allele remains within accessi-
ble domains (2–4). She later focused on 
one of the more curious aspects of allelic 
exclusion. During rearrangement, the Ig 
locus contracts, allowing V, D, and J 
segments to get close to each other and 
join up. Skok found that the successful 
rearrangement of one allele triggers locus 
relaxation, thereby stopping rearrange-
ment of the other allele (5). She is now 
hunting for the proteins and pathways 
that direct the contortion and move-
ment of Ig loci.
A PROMISING START
What inspired you to become a scientist?
There are a mixture of artists and sci-
entists in my family, and I enjoyed both 
disciplines. But solving problems was 
much more satisfying to me, so I chose 
science.
Tell me about your graduate degree in 
genetics.
I worked on the genetics of the fi  rst 
component of the complement system, 
C1q, in Ellen Solomon’s lab. We showed 
that C1q is encoded by distinct sets of 
genes in fi  broblasts and serum. This was 
my fi  rst paper, which I published in a 
relatively short time in Nature. This gave 
me an unrealistic outlook of what I 
would face in the future. I remember 
thinking, “Oh, wow, this is so easy.”
What happened then?
My second child got sick. It’s very hard 
to work when you have young children. 
But when you’ve got a sick child and 
you’re in and out of hospitals all the 
time, it’s almost impossible. I managed to 
fi  nish my Ph.D., but I stopped after that 
for almost ten years.
A PROLONGED STOP
What did you do during that time?
I took care of my child until she got better 
and then had two more children. I en-
joyed being with my children but was 
bored without the challenge of a career. 
I’ve always enjoyed art, so I went to art 
school. Although that was a good ex-
perience, it wasn’t very challenging. I 
missed having the pressure of a focused 
job. So I decided to go back to science.
What did the kids think about that 
decision?
I don’t think the older ones minded 
because they were growing up and 
didn’t need me as much. I went back 
soon after my youngest daughter was 
born. She was too young to know any 
better and hadn't begun to talk yet—
so she couldn’t tell me anything.
What was it like to return to science after 
ten years?
I hadn’t kept up with the literature and 
had forgotten a lot of what I had learned. 
I decided to start by doing a Master's 
degree, thinking that it would be a good 
way of learning and getting oriented in 
whatever fi  eld I was going to go into. I 
decided to study immunology because 
I’d had some exposure to it when I was 
working on C1q in Ellen’s lab.
But it was a tough beginning because 
immunology is not the easiest subject to 
go into. I was reading like crazy to make 
sense of it all. But between the children 
and the studying, it was pretty hard going. 
It was also quite a challenge making my 
brain work after ten years. I had zero 
confidence at that point and felt that I 
wasn’t going to make it.
What made you keep going?
The thought that if I didn’t get back into 
it, I’d be standing in the same place in 
another ten years’ time. That was a scary 
thought because I didn’t want to be 
doing nothing for the rest of my life; I 
wanted it to have some meaning.
During my Master's, I did a short 
research project with David Gray, who 
was a great mentor. He’s one of those 
people who can see the point of some-
thing very clearly without getting bogged 
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down in lots of information—a problem 
that I was experiencing. He also educated 
me about funding opportunities and sup-
ported me in applying for a Wellcome 
Trust Career Reentry Award, which is a 
grant that enables you to get back into sci-
ence after taking a break. I don’t know if 
there’s an equivalent funding program 
here in the US, but it provides a very good 
opportunity for people who’ve had a ca-
reer break to get back in the game. In the 
UK, mostly women apply for it. When I 
later met some of those women, I found 
out that we had all faced the same problem 
going back to science: lack of confidence.
BACK ON TRACK
What did you work on when you got 
back to the lab?
I started to work in David’s lab on how 
cytokines produced by B cells infl  uence 
the diff  erentiation of T cells. Within a 
year of getting my funding, he moved to 
Edinburgh, but luckily, by that time, we 
had enough data to publish a paper.
Was David’s move a setback for you?
No, it actually ended up working in my 
favor. This is how collaborations and inter-
disciplinary science comes about. Mandy 
Fisher, who was in the next building, was 
looking at the positioning of Ikaros in 
resting versus activated B cells. I was help-
ing her purify the cells, and when she 
heard David was leaving, she off  ered me a 
position in her lab to look at where Ig 
genes were positioned in the nucleus. So I 
was doing new things again and was back 
in the land of “Don’t know anything.”
What was your experience in Mandy’s lab?
Like David, Mandy is a clear-thinking 
person who helped me focus. Although 
I was back to square one again and read-
ing papers and textbooks, I managed to 
get things working. I showed that one of 
the Ig alleles is repositioned at repressive 
pericentromeric domains in activated 
mature B cells and that this is important 
for maintaining expression of only one 
allele. At the end of my time in Mandy’s 
lab I successfully applied for a Wellcome 
Trust University award, which came 
with tenure at UCL.
While I was in Mandy’s lab, I got to 
work with Steven Kosak. He had shown 
that Ig loci are initially located at the cell 
periphery in non–B cells but then con-
tract and move toward the center in B 
cells. In collaboration with Steven and 
also Harinder Singh, I did 3D FISH 
experiments to visualize the localization 
of Ig loci in B cells. We found that Ig 
genes move in from the periphery as 
they undergo rearrangement and that 
they contract as they move.
How is this contraction regulated?
This was work I did in collaboration 
with Meinrad Busslinger in Vienna, who 
had asked me if I’d be interested in doing 
some FISH experiments to look at the 
IgH locus in B cells lacking the tran-
scription factor Pax5. That’s when I 
discovered that Pax5 is necessary for 
locus contraction of the Ig heavy chain.
Back in my own lab, we soon found 
that the Ig locus decontracts as soon as the 
heavy chain has finished 
rearranging. We then went 
on to show that contrac-
tion also occurs at the Ig 
kappa (light chain) locus 
during recombination, and 
that one allele is reposi-
tioned at heterochromatic 
domains before rearrange-
ment occurs, which is the 
opposite of what happens 
with the heavy chain locus. 
This work was done in collaboration with 
Yehudit Bergman and later with Marjorie 
Shapiro and Sean Fitzsimmons.
THE NEXT STEPS
If both alleles contract and can recombine, 
what prevents simultaneous rearrangement 
of both alleles?
That’s a fantastic question that we’re work-
ing on at the moment. The fact that only 
one allele gets functionally rearranged 
implies that there’s a mechanism for pre-
venting simultaneous rearrangement on 
both alleles. Fred Alt fi  rst proposed this 
idea back in 1992. We are trying to under-
stand how the positioning of the two 
alleles regulates this and to determine 
what role the recombinase enzymes play.
Sounds like you’ve got enough on your 
plate to stay busy for a while.
I think it’s good to have a long-term 
project because it really gets you focused 
on something. I didn’t really get hooked 
into science until I got hooked into this 
project. I am very impatient about get-
ting data because I always want to know 
the answer to the next question, and I 
want to know it yesterday.
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In developing B cells, only the excluded allele (red and green) is positioned at repressive 
centromeric domains (blue).
“I always want 
to know the 
answer to the 
next question, 
and I want 
to know it 
yesterday.”